Catalent Inc (NYSE:CTLT), a leader in providing drug delivery technology solutions, has recently gone through several noteworthy events.
Curi RMB Capital LLC, Nomura Holdings Inc, and Norris Perne & French LLP MI have significantly reduced their positions in the company. At the same time, CTLT has been acquired by other major stakeholders, including
ING Groep NV, Van ECK Associates Corp, and Olympiad Research LP. This has occurred amidst a pending acquisition by
Novo Holdings. Meanwhile, the firm reported a Q1 loss, and its Revenue lagged estimates, which triggered fluctuation in the stock's performance. However, Catalent's gross margin is up, and it beat Q4 earnings and revenue estimates. Still, the acquisition offer from Novo Holdings has met some resistance, with parties such as Roche and Consumer, Labor groups requesting the FTC to block the deal. Despite all, CTLT continues to make strategic moves within the sector, including selling off its Somerset, NJ Oral Solids Facility, while also announcing the completion of a $25 Million expansion of its clinical supply facility in Germany.
Catalent CTLT News Analytics from Thu, 14 Apr 2016 07:00:00 GMT to Sat, 16 Nov 2024 07:27:31 GMT -
Rating 2
- Innovation 3
- Information 7
- Rumor -3
